BZL Biologics Report issue

For profit Phase 2
Founded: New York NY United States (1994)
Status: Defunct (2003)

Organization Overview

First Clinical Trial
2002
NCT00040586
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2002

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

111in-j591 (1 trial)

aldesleukin (Proleukin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2